Literature DB >> 21487109

Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults.

Itziar Salaverria1, Claudia Philipp, Ilske Oschlies, Christian W Kohler, Markus Kreuz, Monika Szczepanowski, Birgit Burkhardt, Heiko Trautmann, Stefan Gesk, Miroslaw Andrusiewicz, Hilmar Berger, Miriam Fey, Lana Harder, Dirk Hasenclever, Michael Hummel, Markus Loeffler, Friederike Mahn, Idoia Martin-Guerrero, Shoji Pellissery, Christiane Pott, Michael Pfreundschuh, Alfred Reiter, Julia Richter, Maciej Rosolowski, Carsten Schwaenen, Harald Stein, Lorenz Trümper, Swen Wessendorf, Rainer Spang, Ralf Küppers, Wolfram Klapper, Reiner Siebert.   

Abstract

The prognosis of germinal center-derived B-cell (GCB) lymphomas, including follicular lymphoma and diffuse large-B-cell lymphoma (DLBCL), strongly depends on age. Children have a more favorable outcome than adults. It is not known whether this is because of differences in host characteristics, treatment protocols, or tumor biology, including the presence of chromosomal alterations. By screening for novel IGH translocation partners in pediatric and adult lymphomas, we identified chromosomal translocations juxtaposing the IRF4 oncogene next to one of the immunoglobulin (IG) loci as a novel recurrent aberration in mature B-cell lymphoma. FISH revealed 20 of 427 lymphomas to carry an IG/IRF4-fusion. Those were predominantly GCB-type DLBCL or follicular lymphoma grade 3, shared strong expression of IRF4/MUM1 and BCL6, and lacked PRDM1/BLIMP1 expression and t(14;18)/BCL2 breaks. BCL6 aberrations were common. The gene expression profile of IG/IRF4-positive lymphomas differed from other subtypes of DLBCL. A classifier for IG/IRF4 positivity containing 27 genes allowed accurate prediction. IG/IRF4 positivity was associated with young age and a favorable outcome. Our results suggest IRF4 translocations to be primary alterations in a molecularly defined subset of GCB-derived lymphomas. The probability for this subtype of lymphoma significantly decreases with age, suggesting that diversity in tumor biology might contribute to the age-dependent differences in prognosis of lymphoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21487109     DOI: 10.1182/blood-2011-01-330795

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  64 in total

1.  Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients.

Authors:  K K Wong; D M Gascoyne; P J Brown; E J Soilleux; C Snell; H Chen; L Lyne; C H Lawrie; R D Gascoyne; L M Pedersen; M B Møller; K Pulford; D Murphy; T M Green; A H Banham
Journal:  Leukemia       Date:  2013-07-25       Impact factor: 11.528

Review 2.  ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study.

Authors:  Ilske Oschlies; Jasmin Lisfeld; Laurence Lamant; Atsuko Nakazawa; Emanuele S G d'Amore; Ulrika Hansson; Konnie Hebeda; Ingrid Simonitsch-Klupp; Jadwiga Maldyk; Leonhard Müllauer; Marianne Tinguely; Markus Stücker; Marie-Cecile Ledeley; Reiner Siebert; Alfred Reiter; Laurence Brugières; Wolfram Klapper; Wilhelm Woessmann
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

3.  Bone marrow stromal cells induced activation of nuclear factor κB signaling protects non-Hodgkin's B lymphoma cells from apoptosis.

Authors:  Tuo Su; Jiakai Li; Mingming Meng; Sheng Zhao; Yali Xu; Xinmin Ding; Hong Jiang; Xiaorong Ma; Jin Qian; Wei Han; Lixin Sun; Xiaobin Li; Zuojun Liu; Lei Pan; Xinying Xue
Journal:  Tumour Biol       Date:  2016-02-12

4.  The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma.

Authors:  Rebecca L Boddicker; N Sertac Kip; Xiaoming Xing; Yu Zeng; Zhi-Zhang Yang; Jeong-Heon Lee; Luciana L Almada; Sherine F Elsawa; Ryan A Knudson; Mark E Law; Rhett P Ketterling; Julie M Cunningham; Yanhong Wu; Matthew J Maurer; Megan M O'Byrne; James R Cerhan; Susan L Slager; Brian K Link; Julie C Porcher; Deanna M Grote; Diane F Jelinek; Ahmet Dogan; Stephen M Ansell; Martin E Fernandez-Zapico; Andrew L Feldman
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

5.  Follicular lymphomas: a tapestry of common and contrasting threads.

Authors:  Elaine S Jaffe
Journal:  Haematologica       Date:  2013-08       Impact factor: 9.941

Review 6.  Diagnosis and classification of lymphoma: Impact of technical advances.

Authors:  Elaine S Jaffe
Journal:  Semin Hematol       Date:  2018-05-29       Impact factor: 3.851

Review 7.  Recommendations for Clinical Trial Development in Follicular Lymphoma.

Authors:  Kami Maddocks; Paul M Barr; Bruce D Cheson; Richard F Little; Lawrence Baizer; Brad S Kahl; John P Leonard; Nathan Fowler; Leo I Gordon; Brian K Link; Jonathan W Friedberg; Stephen M Ansell
Journal:  J Natl Cancer Inst       Date:  2016-12-31       Impact factor: 13.506

8.  Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma.

Authors:  Sietse M Aukema; Markus Kreuz; Christian W Kohler; Maciej Rosolowski; Dirk Hasenclever; Michael Hummel; Ralf Küppers; Dido Lenze; German Ott; Christiane Pott; Julia Richter; Andreas Rosenwald; Monika Szczepanowski; Carsten Schwaenen; Harald Stein; Heiko Trautmann; Swen Wessendorf; Lorenz Trümper; Markus Loeffler; Rainer Spang; Philip M Kluin; Wolfram Klapper; Reiner Siebert
Journal:  Haematologica       Date:  2013-10-31       Impact factor: 9.941

9.  An activating mutation of interferon regulatory factor 4 (IRF4) in adult T-cell leukemia.

Authors:  Mathew A Cherian; Sydney Olson; Hemalatha Sundaramoorthi; Kitra Cates; Xiaogang Cheng; John Harding; Andrew Martens; Grant A Challen; Manoj Tyagi; Lee Ratner; Daniel Rauch
Journal:  J Biol Chem       Date:  2018-03-14       Impact factor: 5.157

Review 10.  [Grey zone lymphomas: limitations of the classification of aggressive B-cell lymphomas].

Authors:  M M Ott; H Horn; A Rosenwald; G Ott
Journal:  Pathologe       Date:  2013-05       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.